



# Remote control of Diels–Alder additions. Enantioselective synthesis of (2*R*)-1,2,3,4-tetrahydro-2-hydroxy-5,8-dimethoxynaphthalen-2-yl methyl ketone (Wong's anthracycline intermediate) from furfural

Viviane Theurillat-Moritz, Antonio Guidi<sup>†</sup> and Pierre Vogel<sup>\*</sup>


Section de chimie de l'Université de Lausanne, BCH, CH-1015 Lausanne-Dorigny, Switzerland

**Abstract:** The enantiomerically pure (1*S*,4*R*,4'*S*,5'*S*)-1-(4',5'-dimethyl-dioxolan-2'-yl)-5,6-dimethylidene-7-oxabicyclo[2.2.1]hept-2-ene derived from the acetal of furfural and (2*S*,3*S*)-butane-2,3-diol underwent addition to 1-acetylvinyl *para*-nitrobenzoate in the presence of an excess of *t*-BuMe<sub>2</sub>SiOSO<sub>2</sub>CF<sub>3</sub> to yield an 83:17 mixture of two diastereomeric products which was converted into (2*R*)-1,2,3,4-tetrahydro-2-hydroxy-5,8-dimethoxynaphthalen-2-yl methyl ketone. © 1997 Elsevier Science Ltd

## Introduction

The Diels–Alder cycloadditions of diene **1** and tetraene **2** have been shown to be regioselective when using methyl vinyl ketone or 2-butyne as dienophiles. The regioselectivity is at its highest when the reactions are carried out at low temperature in the presence of a large excess of a strong Lewis acid.<sup>1,2</sup> Regio- and stereo-control by the 1-(dimethoxymethyl) group are quite good with 1-acetylvinyl esters **3**. For instance, the BF<sub>3</sub>·Et<sub>2</sub>O-promoted Diels–Alder addition of 1-acetylvinyl RADO(Et)-ate (**3a**; RADO(Et)=(1*R*,7*R*)-3-ethyl-2-oxo-6,8-dioxo-3-azabicyclo[3.2.1]octane-7-*exo*-carbonyl)<sup>3</sup> to tetraene **2** leads to an 87:13 mixture of the monoadducts **4** and **4'**. Adduct **4** was converted into (–)-4-demethoxy-7-deoxydaunomycinone and led to a new class of enantiomerically pure anthracycline analogues.<sup>4</sup>

Recently we described the synthesis of enantiomerically pure triene (+)-**5**, derived from the acetal of furfural and (2*S*,3*S*)-butane-2,3-diol in four steps.<sup>5</sup> We report here the results of our studies on its cycloaddition to 1-acetylvinyl 4-nitrobenzoate **3b** and the conversion of the adducts obtained into Wong's intermediate,<sup>6,7</sup> of use to generate anthracycline anti-tumor drugs.<sup>8,9</sup>




<sup>\*</sup> Corresponding author.

<sup>†</sup> Present address: A. Menarini, Via Sette Santi 8, I-50131 Firenze, Italy.

### Results and discussion

As expected<sup>10</sup>, triene (+)-5 was much less reactive than diene **1** and tetraene **2** towards all kinds of dienophiles. With **3b**,<sup>11</sup> Lewis acids such as B(OMe)<sub>3</sub>, BF<sub>3</sub>·Et<sub>2</sub>O, Yb(OTf)<sub>3</sub> were not capable of promoting the Diels–Alder cycloaddition without extensive polymerization. We eventually found that *t*-BuMe<sub>2</sub>SiOSO<sub>2</sub>CF<sub>3</sub> (4 equivalents) was capable of inducing a smooth addition (CH<sub>2</sub>Cl<sub>2</sub>, –78°C, 7 days) providing aldehyde (+)-6 (70%) after work-up with aqueous NaHCO<sub>3</sub>. Bayer–Villiger oxidation of (+)-6 with *meta*-chloroperbenzoic acid (*m*-CPBA) in CH<sub>2</sub>Cl<sub>2</sub> (0°C) led to tetraline (–)-7 (80%) with an e.e.=66%, as measured by <sup>19</sup>F-NMR of its Mosher's ester.<sup>12</sup> Its absolute configuration (2*R*) was established as follows (Scheme 1): methylation of (–)-7 with K<sub>2</sub>CO<sub>3</sub>, Me<sub>2</sub>SO<sub>4</sub> in THF (65°C, 2 days, Ar) followed by methanolysis (MeOH, 65°C, 2 h) furnished the known Wong's intermediate (–)-8 (62%).<sup>7</sup>




Scheme 1.

The enantiomeric excess of 66% obtained for (–)-8 does not arise from epimerization which has been reported to occur under acidic conditions.<sup>13</sup> When the cycloaddition between **3b** and (+)-5 was carried out in a NMR tube (CD<sub>2</sub>Cl<sub>2</sub>, –78°C), the slow formation of two diastereomeric cyclohexadienyl cations **10** and **10'** was observed indicating that the Lewis-acid (*t*-BuMe<sub>2</sub>SiOSO<sub>2</sub>CF<sub>3</sub>) used to promote the Diels–Alder addition induces a fast oxa-ring opening of the 7-oxanorbornadiene intermediates **9**. Structures of cations **10** and **10'** were given by their <sup>13</sup>C-NMR characteristics (see Experimental part) which compared well with those reported for the 1,3,5-trimethylcyclohexadienyl cation in super-acid media.<sup>14</sup> On warming the solution to 0°C, cations **10** and **10'** eliminated a proton providing a 83:17 mixture of silyl phenolates **11** and **11'** (as given by their <sup>13</sup>C-NMR data). At 20°C, and in the presence of H<sub>2</sub>O, **11** and **11'** were rapidly hydrolyzed to (+)-6 (Scheme 2).

These observations demonstrate that the incomplete enantiomeric purity of (+)-6, (–)-7 and (–)-8 arises from an incomplete stereoselectivity of the Diels–Alder addition of **3b** to triene (+)-5. As in the case of the cycloaddition of **3b** to tetraene **2**, the cycloaddition **3b**+(+)-5 is highly regioselective but the face and/or *Alder* vs anti-*Alder* stereoselectivity of the reaction is incomplete, in contrast with the cycloaddition **2**+**3a**→**4**+**4'**.<sup>4</sup>

### Conclusion

The enantiomerically enriched (e.e. 66%) Wong's intermediate for anthracycline synthesis has been derived in seven steps from the acetal of furfural and (2*S*,3*S*)-butane-2,3-diol. Our approach features a highly regioselective but incompletely stereoselective Diels–Alder addition of 1-acetylviny *para*-nitrobenzoate to (1*S*,4*R*,4'*S*,5'*S*)-1-(4',5'-dimethyldioxolan-2'-yl)-5,6-dimethylidene-7-oxabicyclo[2.2.1]hept-2-ene.



Scheme 2.

### Experimental

General, see Ferritto and Vogel.<sup>15</sup> None of the procedures were optimized. All solvents were distilled prior to use.  $\text{CH}_2\text{Cl}_2$  was distilled from  $\text{P}_2\text{O}_5$ . TLC monitoring: Merck silica gel 60 F<sub>254</sub> plates, detection by UV light or phosphomolybdic acid and heat. Flash chromatography (FC): Merck silica gel 60 (63–200  $\mu\text{m}$ ).

#### (2R)-Acetyl-5-formyl-1,2,3,4-tetrahydro-8-hydroxynaphthalen-2-yl para-nitrobenzoate (+)-6

1-Acetylvinyl *p*-nitrobenzoate<sup>11</sup> (50 mg, 0.247 mmol) was dissolved in anhydrous  $\text{CH}_2\text{Cl}_2$  (1 ml) and was cooled to  $-78^\circ\text{C}$  under an Ar atmosphere.  $t\text{-BuMe}_2\text{SiOSO}_2\text{CF}_3$  (90  $\mu\text{l}$ , 0.392 mmol) was added and the solution was stirred at  $-78^\circ\text{C}$  for 1 h. Triene (+)-5<sup>5</sup> (20 mg, 0.908 mmol) was then added and the mixture was allowed to react at  $-78^\circ\text{C}$  without stirring for 1 week. The solution was then poured into sat. aq.  $\text{NaHCO}_3$  sol. (3 ml) and ice (4 g) and was stirred for 1 h. The mixture was then extracted with  $\text{CH}_2\text{Cl}_2$  (10 ml, twice). The organic phases were washed with water (5 ml), sat. aq.  $\text{NaCl}$  sol. (5 ml), dried ( $\text{MgSO}_4$ ) and the solvent was evaporated without heating. The residue was purified by FC (Florisil, light petroleum/EtOAc 2:1) yielding 25 mg (70%), (colourless oil); e.e.=66% as determined for (–)-7.  $[\alpha]_{589}^{25}=310$ ,  $[\alpha]_{578}^{25}=346$ ,  $[\alpha]_{546}^{25}=381$ ,  $[\alpha]_{436}^{25}=890$  ( $c=0.42$ ,  $\text{CHCl}_3$ ). UV ( $\text{CH}_3\text{CN}$ ): 268 (11000); 227 (6000). IR (KBr): 3420, 1723, 1674, 1580, 1527, 1351, 1293, 1231, 1104, 721.  $^1\text{H-NMR}$  (250 MHz,  $\text{CDCl}_3$ ): 10.02 (*s*, CHO); 8.27 (*d*,  $^3J=8.8$ , PNB); 8.12 (*d*,  $^3J=8.8$ , PNB); 7.62 (*d*,  $^3J=8.3$ , H–C(6)); 6.83 (*d*,  $^3J=8.3$ , H–C(7)); 3.57 (*ddd*,  $^2J=18.5$ ,  $^3J=5.5$ , 4.2, H–C(4)); 3.32 (*br s.*, H<sub>2</sub>–C(1)); 3.25 (*ddd*,  $^2J=18.5$ ,  $^3J=11.3$ , 5.5, H–C(4)); 2.62 (*ddd*,  $^2J=14.0$ ,  $^3J=5.5$ , 4.2, H–C(3)); 2.30 (*s*, Me); 2.11 (*ddd*,  $^2J=14.0$ ,  $^3J=11.3$ , 5.5, H–C(3)).  $^{13}\text{C-NMR}$  (100.6 MHz,  $\text{CDCl}_3$ ): 205.6 (*s*, CO); 192.1 (*d*,  $^1J(\text{C,H})=172$ , CHO); 163.9 (*s*, COO); 159.3, 150.8, 139.4 (3*s*, C(arom)); 135.1, 130.9, 123.6 (3*d*,  $^1J(\text{C,H})=169$ , 171, C(arom)); 121.1 (*s*, C(arom)); 112.5 (*d*,  $^1J(\text{C,H})=161$ , C(arom)); 84.4 (*s*, C(2)); 29.4, 27.5, 22.9 (3*t*,  $^1J(\text{C,H})=129$ , 131, 130, C(1), C(3), C(4)); 24.0 (*q*,  $^1J(\text{C,H})=128$ , Me). CI-MS ( $\text{NH}_3$ ): 402 (0.5,  $[\text{M}+\text{NH}_4]^+$ ), 337 (0.5,  $[\text{M}-\text{NO}_2]^+$ ), 260 (21,  $[\text{M}-\text{C}_6\text{H}_5\text{NO}_2]^+$ ), 217 (2,  $[\text{M}-\text{CO}_2\text{C}_6\text{H}_4\text{NO}_2]^+$ ), 179 (14), 178 (42), 169 (44), 167 (52), 139 (41), 111 (48), 86 (63), 84 (100), 83 (39), 72 (49). Anal. calc. for  $\text{C}_{20}\text{H}_{17}\text{NO}_7$  (383.1): C 62.66, H 4.47, N 3.65; found: C 62.59, H 4.62, N 3.67.

#### (2R)-2-Acetyl-5-formyloxy-1,2,3,4-tetrahydro-8-hydroxynaphthalen-2-yl para-nitrobenzoate ((–)-7)

A mixture of (+)-6 (70 mg, 0.204 mmol),  $\text{NaHCO}_3$  (35 mg, 0.408 mmol) and anhydrous  $\text{CH}_2\text{Cl}_2$  (7 ml) was cooled to  $0^\circ\text{C}$ . *m*-CPBA (100%, 44 mg, 0.2548 mmol) was added and the solution was stirred at  $0^\circ\text{C}$  for 3 h. The mixture was poured into water and ice (10 ml) and extracted with  $\text{CH}_2\text{Cl}_2$  (20 ml, 3 times). After drying ( $\text{MgSO}_4$ ), the solvent was evaporated and the residue was purified by FC

(silica gel, CH<sub>2</sub>Cl<sub>2</sub>/light petroleum/EtOAc 8:1:1), yielding 66 mg (80%), yellowish powder (e.e.=66%, Mosher's ester, <sup>19</sup>F-NMR). [ $\alpha$ ]<sub>589</sub><sup>25</sup> = -18.5, [ $\alpha$ ]<sub>577</sub><sup>25</sup> = -19.5, [ $\alpha$ ]<sub>546</sub><sup>25</sup> = -23.0, [ $\alpha$ ]<sub>435</sub><sup>25</sup> = -33.4 (c=1.1, CHCl<sub>3</sub>). IR (KBr): 3434, 2937, 1723, 1528, 1465, 1351, 1321, 1293, 1244, 1117, 1103, 737, 720. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 8.28 (s, HCOO); 8.26 (*md*, <sup>3</sup>J=8.7, H(arom)); 8.09 (*md*, <sup>3</sup>J=8.7, H(arom)); 6.87, 6.67 (*2d*, <sup>3</sup>J=8.6, H-C(6), H-C(7)); 3.37 (*br. d*, <sup>2</sup>J=18.2, H-C(1)); 3.18 (*br. d*, <sup>2</sup>J=18.2, H-C(1)); 2.85 (*br. ddd*, <sup>2</sup>J=17.7, <sup>3</sup>J=5.9, 2.7, H-C(3)); 2.68 (*br. m*, H-C(3)); 2.59 (*br. m*, H-C(4)); 2.31 (s, CH<sub>3</sub>); 2.10 (*m*; H-C(4)). <sup>13</sup>C-NMR (100.6 MHz, CDCl<sub>3</sub>): 205.7 (s, CO); 164.1 (s, COO); 159.6 (*d*, <sup>1</sup>J(C,H)=231, HCOO); 152.0, 150.8, 140.9, 134.5 (4s, C(arom)); 131.0 (*d*, <sup>1</sup>J(C,H)=170, C(arom)); 128.1 (s, C(arom)); 123.7 (*d*, <sup>1</sup>J(C,H)=172, C(arom)); 121.0 (s, C(arom)); 119.6, 112.9 (*2d*, <sup>1</sup>J(C,H)=164, 162, C(arom)); 84.6 (s, C(2)); 29.7, 26.8 (*2t*, <sup>1</sup>J(C,H)=130, 131, C(1), C(3)); 24.2 (*q*, <sup>1</sup>J(C,H)=129, CH<sub>3</sub>); 20.0 (*t*, <sup>1</sup>J(C,H)=130, C(4)). CI-MS (NH<sub>3</sub>): 415 (7, [M+NH<sub>4</sub>]<sup>+</sup>), 400 (4, [M+H]<sup>+</sup>), 399 (2, M<sup>+</sup>), 343 (8), 281 (6), 234 (19), 233 (54), 232 (100), 204 (19), 189 (20), 187 (79), 161 (27), 150 (78), 137 (34), 120 (62), 92 (43).

*(2R)-2-Acetyl-1,2,3,4-tetrahydro-5,8-dihydroxynaphthalen-2-yl para-nitrobenzoate*

This compound was formed quantitatively when (-)-7 was left in presence of air. Colourless oil. IR (film): 3385 (*br*), 2921, 2360, 2339, 1722, 1716, 1651, 1537, 1489, 1351, 1292, 1103, 720. <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): 8.27 (*dm*, <sup>3</sup>J=8.9, H(arom)); 8.10 (*dm*, <sup>3</sup>J=8.9, H(arom)); 6.57, 6.54 (*2d*, <sup>3</sup>J=9.5, H-C(6), H-C(7)); 4.52, 4.42 (*2br. s*, 2×OH); 3.33 (*br. dd*, <sup>2</sup>J=17.6, <sup>4</sup>J=1.5, H-C(1)); 3.16 (*br. d*, <sup>2</sup>J=17.6, H-C(1)); 2.95, 2.66, 2.12 (*3m*, H<sub>2</sub>-C(3), H<sub>2</sub>-C(4)); 2.30 (s, CH<sub>3</sub>). <sup>13</sup>C-NMR (100.6 MHz, CDCl<sub>3</sub>): 205.5 (s, CO); 163.9 (s, COO); 150.7, 147.3, 146.7 (*3s*, C(arom)); 130.9, 123.7, 123.6 (*3d*, C(arom)); 122.7, 120.6 (*2s*, C(arom)); 112.6 (*d*, C(arom)); 84.9 (s, C(2)); 29.9, 26.6, 20.2 (*3t*, C(1), C(3), C(4)); 24.2 (*q*, CH<sub>3</sub>). CI-MS (NH<sub>3</sub>): 389 (43, [M+NH<sub>4</sub>]<sup>+</sup>), 388 (26), 387 (100), 372 (25 [M+H]<sup>+</sup>), 371 (20, M<sup>+</sup>), 370 (71), 313 (24), 295 (18), 254 (11), 216 (19), 199 (28), 152 (71), 108 (29), 91 (42).

*(2R)-1,2,3,4-Tetrahydro-2-hydroxy-5,8-dimethoxynaphthalen-2-yl methyl ketone ((-)-8)*

A mixture of (-)-7 (20 mg, 0.050 mmol), anh. THF (5 ml), K<sub>2</sub>CO<sub>3</sub> (200 mg, 1.45 mmol) and Me<sub>2</sub>SO<sub>4</sub> (100 μl, 0.793 mmol) was refluxed under Ar for 2 days. Anh. MeOH (1 ml) was then added and the solution was refluxed for 2 hours (TLC control, silica gel, CH<sub>2</sub>Cl<sub>2</sub>/light petroleum/EtOAc 8:1:1). The mixture was then poured into 1 N aqueous HCl (10 ml) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (20 ml, 3 times). After drying (MgSO<sub>4</sub>), the solvent was evaporated and the residue was purified by FC (silica gel, CH<sub>2</sub>Cl<sub>2</sub>/light petroleum/EtOAc 17:2:1), yielding 7.8 mg (62%), colourless oil (e.e.=66%), [ $\alpha$ ]<sub>589</sub><sup>25</sup> = -22 (c=0.8, CHCl<sub>3</sub>). All spectral data were identical to those reported for this compound.<sup>6,7</sup> Anal. calc. for C<sub>14</sub>H<sub>18</sub>O<sub>4</sub> (250.29): C 67.18, H 7.25; found C 67.31, H 7.08.

Characteristics of the major intermediates **10** and **11** formed during the *t*-BuMe<sub>2</sub>SiOSO<sub>2</sub>CF<sub>3</sub>-promoted cycloaddition of **3b** to (+)-5. <sup>13</sup>C-NMR (CD<sub>2</sub>Cl<sub>2</sub>, 100.6 MHz, -78°C) of **10**: 207.7 (CO), 174.1 (C(5)), 166.0 (COO), 150.9, 150.0 (C(7), C(8a)), 100.3 (C(2')), 94.5 (C(8)), 85.0 (C(2)), 72.7, 72.3 (C(4'), C(5')), 24.8, 22.9 (Me-C(4'), Me-C(5')). <sup>13</sup>C-NMR (CD<sub>2</sub>Cl<sub>2</sub>, 100.6 MHz, 0°C) of **11**: 207.2 (CO), 166.0 (COO), 105.2 (C(2')), 85.1 (C(2')), 81.5, 80.5 (C(4'), C(5')), 18.3, 17.7 (Me-C(4'), Me-C(5')). Signals for C(1), C(3), C(4), C(4a), C(6) and MeCO are overlapped with those of the reactants.

### Acknowledgements

We thank the Swiss National Science Foundation (CHiral2 program) and the Fondation Herbette (Lausanne) for generous financial support. We are grateful also to Mr Martial Rey and to Mr Francisco Sepulveda for their technical help.

### References

1. Métral, J.-L.; Vogel, P. *Tetrahedron Lett.* **1984**, *25*, 5387-5388.
2. Métral, J.-L.; Lauterwein, J.; Vogel, P. *Helv. Chim. Acta* **1986**, *69*, 1287-1309.
3. Reymond, J.-L.; Vogel, P. *Tetrahedron: Asymmetry* **1990**, *1*, 729-736.

4. Dienes, Z.; Vogel, P. *J. Org. Chem.* **1996**, *61*, 6958–6970.
5. Guidi, A.; Theurillat-Moritz, V.; Vogel, P.; Pinkerton, A. A. *Tetrahedron: Asymmetry* **1996**, *7*, 3153–3162.
6. Wong, C. M.; Popien, D.; Schwenk, R.; Te Raa, J. *Can. J. Chem.* **1971**, *49*, 2712–2718.
7. Arcamone, F.; Bernardi, L.; Patelli, B.; Giardino, P.; Di Marco, A.; Casazza, A. M.; Soranzo, C.; Pratesi, G. *Experientia* **1978**, *34*, 1255–1257; Broadhurst, M. J.; Hassall, C. H.; Thomas, G. *J. J. Chem. Soc., Perkin Trans. I* **1982**, 2239–2248, 2249–2255; Swenton, J. S.; Freskos, J. N.; Morrow, G. W.; Sercel, A. D. *Tetrahedron* **1984**, *40*, 4625–4632; Terashima, S.; Jew, S.-S.; Koga, K. *Tetrahedron Lett.* **1978**, *19*, 4937–4940; Terashima, S.; Tamoto, K. *Ibid.* **1982**, *23*, 3715–3718; Suzuki, M.; Kimura, Y.; Terashima, S. *Chem. Lett.* **1985**, 367–370; Suzuki, M.; Kimura, Y.; Terashima, S. *Tetrahedron Lett.* **1985**, *26*, 6481–6484; Suzuki, M.; Kimura, Y.; Terashima, S. *Bull. Chem. Soc. Jpn.* **1986**, *59*, 3559–3572; Hatakeyama, S.; Sugawara, K.; Takano, S. *J. Chem. Soc., Chem. Comm.* **1991**, 1533–1534; Davis, F. A.; Kumar, A.; Chen, B.-C. *Tetrahedron Lett.* **1991**, *32*, 867–870; Rama Rao, A. V.; Yadav, J. S.; Bal Reddy, K.; Mehendale, A. R. *J. Chem. Soc., Chem. Comm.* **1984**, 453–455; Rama Rao, A. V.; Yadav, J. S.; Bal Reddy, K.; Mehendale, A. R. *Tetrahedron* **1984**, *40*, 4643–4647; Sodeoka, M.; Iimori, T.; Shibasaki, M. *Tetrahedron Lett.* **1985**, *26*, 6497–6500; Nakajima, M.; Tomioka, K.; Koga, K. *Tetrahedron* **1993**, *49*, 10807–10816.
8. Arcamone, F. M.; Bernardi, L.; Patelli, B.; Di Marco, A.; Ger Offen 2601785, *Chem. Abstr.* **1976** **85**: P 142918 j.
9. See e.g.: Lown, L. W. *Chem. Soc. Rev.* **1993**, 165–176; Priebe, W. *Anthracycline Antibiotics: New Analogues, Methodes of Delivery and Mechanisms of Action*; ACS Symposium Series 574; American Chemical Society: Washington, D.C., 1995; Weiss, R. B. *Semin. Oncol.* **1992**, *19*, 670–686.
10. Hardy, M.; Carrupt, P.-A.; Vogel, P. *Helv. Chim. Acta* **1976**, *59*, 1685–1697; Carrupt, P.-A.; Vogel, P. *Tetrahedron Lett.* **1979**, 4533–4536; Vogel, P. in *Advances in Theoretically Interesting Molecules*, Ed. R. P. Thummel, JAI Press, Inc., Greenwich, CT, USA, **1989**, vol. *1*, p. 201–355; Roulet, J.-M.; Vogel, P.; Wiesemann, F.; Pinkerton, A. A. *Tetrahedron* **1995**, *51*, 1685–1696.
11. Tamariz, J.; Vogel, P. *Helv. Chim. Acta* **1981**, *64*, 188–197.
12. Dale, J. A.; Mosher, H. S. *J. Am. Chem. Soc.* **1973**, *95*, 512–519.
13. Terashima, S.; Tamoto, K. *Tetrahedron Lett.* **1983**, *24*, 2589–2592.
14. Stothers, J. B. in *Carbon-13 NMR Spectroscopy*, Academic Press, New York, **1972**; Olah, G. A.; Schlosberg, R. H.; Kelly, D. P.; Mateescu, G. D. *J. Am. Chem. Soc.* **1970**, *92*, 2546–2548.
15. Ferritto, R.; Vogel, P. *Tetrahedron: Asymmetry* **1994**, *5*, 2077–2092.

(Received in UK 8 September 1997)